QDEL1 Stock Chart & Stats
$570.28
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$570.28 - $570.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$19.08B
Enterprise Value$3.74K
Total Cash (Recent Filing)$140.40M
Total Debt (Recent Filing)$2.87B
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 06, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.85
Shares Outstanding68,190,990
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$237.54Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue DiversificationA high non‑respiratory mix (>88% of Q1 revenue) reduces reliance on volatile respiratory seasonality and supports steadier consumables demand tied to installed instruments. That diversification improves durable revenue visibility and stabilizes recurring pull‑through over multiple quarters.
Product & M&A ExpansionThe Lex acquisition and new test launches (troponin, VITROS 450 rollout) expand the company’s addressable market and create new instrument placements that drive long‑term recurring assay and reagent revenue. This builds multi‑year growth drivers beyond legacy respiratory cycles.
Experienced Financial LeadershipHiring an experienced med‑tech CFO and an orderly transition with the prior CFO advising strengthens capital allocation, execution on margin and cash‑generation targets, and investor communication—key capabilities for sustaining a medium‑term turnaround in profitability.
Bears Say
Elevated LeverageHigh leverage reduces financial flexibility and raises refinancing and interest risk, limiting the company’s ability to fund organic growth or absorb revenue shocks. Even planned deleveraging to ~3.25–3.5x leaves limited headroom and increases vulnerability over the next several quarters.
Weak Cash GenerationNegative free cash flow and deteriorated operating cash flow curtail self‑funding for R&D, capex, and working capital. The company has drawn on revolver capacity, implying ongoing reliance on external financing or sustained cost cuts that could constrain strategic investments.
Profitability & Revenue PressureA swing to sizable losses and declining revenue signals structural headwinds from adverse product mix and weaker demand. Prolonged weak profitability erodes returns, may necessitate persistent cost actions, and raises execution risk for restoring sustainable margins.
QDEL1 FAQ
What was Quidelortho Corporation’s price range in the past 12 months?
Quidelortho Corporation lowest stock price was $570.28 and its highest was $570.28 in the past 12 months.
What is Quidelortho Corporation’s market cap?
Quidelortho Corporation’s market cap is $19.08B.
When is Quidelortho Corporation’s upcoming earnings report date?
Quidelortho Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 9 days.
How were Quidelortho Corporation’s earnings last quarter?
Quidelortho Corporation released its earnings results on May 05, 2026. The company reported -$0.697 earnings per share for the quarter, missing the consensus estimate of $6.224 by -$6.921.
Is Quidelortho Corporation overvalued?
According to Wall Street analysts Quidelortho Corporation’s price is currently Undervalued.
Does Quidelortho Corporation pay dividends?
Quidelortho Corporation does not currently pay dividends.
What is Quidelortho Corporation’s EPS estimate?
Quidelortho Corporation’s EPS estimate is -0.65.
How many shares outstanding does Quidelortho Corporation have?
Quidelortho Corporation has 68,190,990 shares outstanding.
What happened to Quidelortho Corporation’s price movement after its last earnings report?
Quidelortho Corporation reported an EPS of -$0.697 in its last earnings report, missing expectations of $6.224. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Quidelortho Corporation?
Currently, no hedge funds are holding shares in MX:QDEL1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$237.54 (― Downside)
$237.54 (― Downside)
Blogger Sentiment
Bullish
MX:QDEL1 Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.89%
Trailing 12-Months
Company Description
Quidelortho Corporation
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL1 Company Deck
QDEL1 Earnings Call
Q1 2026
0:00 / 0:00
QDEL1 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$237.54
Technical Analysis
1 Day
3 Days
1 Week
1 Month